A study of 9 studies found that higher walking speeds were linked to increased survival time in older adults. Gait speed was most informative after age 75, with faster speeds corresponding to longer expected remaining life.
Survival rates for breast, ovarian, colorectal, and lung cancer are higher in Australia, Canada, and Sweden compared to the UK and Denmark. International differences narrowed for breast cancer, but significant disparities remain in other cancers.
A new study predicts that the Mariana crow will go extinct in 75 years due to a low first-year survival rate of 40%. The species is critically endangered and faces threats from invasive species like feral cats and brown tree snakes.
Research by St. Jude Children's Research Hospital found that intensive chemotherapy significantly increased the cure rate to nearly 88% for older adolescents with acute lymphoblastic leukemia, narrowing the survival gap between older and younger patients.
A new study found that black patients with early-stage liver cancer have a higher mortality rate than white patients, with median survival times ranging from 8-10 months. The disparity in treatment access also affects the survival rates of Hispanic and black patients compared to white patients.
Patients who develop an acne-like skin rash after starting chemotherapy and cetuximab treatment have better overall survival, progression-free survival, and response rates compared to those without a rash. The study suggests that an early skin rash could be a predictor of treatment success in lung cancer patients.
Researchers found that adding ipilimumab to paclitaxel/carboplatin improved progression-free survival rates for stage IIIb/IV non-small cell lung cancer patients. The study suggests that ipilimumab may be a valuable addition to standard treatments, potentially leading to better patient outcomes.
A retrospective study found that obese women with estrogen receptor-positive/HER2-negative breast cancer experienced significantly worse disease-free and overall survival rates compared to non-obese patients. Obesity was not associated with poorer outcomes in HER2-positive or triple-negative breast cancer subtypes.
Phase III trials should aim to find clinically important differences in survival outcomes, rather than just statistically significant ones. Pharmaceutical companies often prioritize minimal but detectable differences that are feasible within trial constraints.
Phase III trial data suggests Tumor Treating Fields (TTF) therapy increases median survival time and improves quality of life scores compared to standard chemotherapy. Younger patients and those with better functional status show an impressive survival advantage.
A randomized phase 2 study found that combining sorafenib with doxorubicin improved median overall and progression-free survival in patients with advanced liver cancer. The study showed a significant reduction in the risk of death and progression, with median overall survival increasing to 13.7 months
A study published in JAMA found that using automated external defibrillators (AEDs) in hospital settings does not improve survival rates for patients experiencing cardiac arrest. The analysis, which included over 11,700 hospitalized patients, showed a 15% lower rate of survival among those who received AED treatment.
Researchers found that administering arsenic trioxide after initial standard treatment improved survival rates for patients with acute promyelocytic leukemia (APL). The study, which involved 481 patients, showed significant benefits in event-free survival and overall survival.
A recent study found that patients with MUTYH-associated polyposis have a statistically significant better survival rate than those with colorectal cancer from the general population. The five-year survival rate for MUTYH-associated polyposis was 78%, compared to 63% for control patients.
A study found that colorectal cancer patients with the KRAS p.G13D gene mutation had longer overall and progression-free survival when treated with cetuximab compared to those with other KRAS mutations. This suggests a potential benefit of cetuximab in certain patients with chemotherapy-refractory metastatic colorectal cancer.
A new study found higher progression-free survival rates for HPV-positive head and neck cancer patients treated with cetuximab and intensity-modulated radiation therapy (IMRT). Patients showed a 100% one-year progression-free survival rate compared to 31% for those without HPV.
A meta-analysis published in The Lancet found that chest compression-only CPR improved survival rates by 22% compared to standard CPR. The study analyzed data from over 3,700 cardiac arrest patients and found the benefit occurred only when 911 dispatchers coached bystanders to use chest compression-only CPR.
A study published in The Lancet found that dispatcher-assisted CPR producing chest compression only results in improved survival rates compared to standard CPR. Continuous uninterrupted chest compressions are vital for successful CPR, and avoiding mouth-to-mouth ventilation increases the probability of a successful outcome.
A Phase IIb/III trial shows afatinib benefits patients with lung adenocarcinoma whose cancer progressed after chemotherapy and erlotinib or gefitinib. Patients receiving afatinib experienced delayed disease progression and greater tumor shrinkage, but no significant difference in overall survival.
Researchers reported that adding cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer did not improve response rates, progression-free survival, or overall survival. The NORDIC VII study included 566 patients and found no statistically significant differences between the treatment groups.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.
Researchers from the Walter and Eliza Hall Institute have discovered a new cell survival protein, Mcl-1, essential for creating and maintaining B cell memory. This finding contradicts existing theories and has implications for cancer treatment and autoimmune disease.
A study by Columbia University's Mailman School of Public Health found that the US life expectancy has fallen behind other countries despite high health spending. The researchers attribute this failure to flaws in the overall healthcare system, including unregulated fee-for-service payments and reliance on specialty care.
A Commonwealth Fund study found that US life expectancy has declined relative to other developed nations, despite higher healthcare spending. The researchers attribute the decline to flaws in the US healthcare system, including unregulated fee-for-service payments and reliance on specialty care.
A vaccine that targets a genetic mutation driving aggressive glioblastoma improved patient survival, with median overall survival of 26 months compared to 15 months for control group. Limited side effects were reported.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
A recent study found that patients without private health insurance had significantly poorer cancer survival rates compared to those with insurance. The study, which analyzed data from 178,891 patients, also found that African-American patients were twice as likely to die within four years of diagnosis.
A retrospective study found that African-American patients had a lower median overall survival rate due to factors such as age, stage, and type of treatment, rather than their race. Patients of other races, including Asian and Hispanic patients, had a better disease prognosis.
A recent study by Mayo Clinic found that radical prostatectomy significantly improves survival rates for men with localized prostate cancer. The procedure has led to excellent overall survival rates, with only 3% of patients dying from prostate cancer.
Researchers found that surgery provides high survival rates of 92% for patients with aggressive prostate cancer, outperforming radiation therapy alone in terms of cancer-specific and overall survival. The study suggests that limiting hormone therapy may avoid adverse health consequences for these patients.
A new study published in The Lancet Oncology found that imatinib treatment interruption after 3 years results in rapid relapse and low progression-free survival. Patients who stopped treatment experienced significant tumour growth and poor overall survival, highlighting the need for continuous treatment to maintain cancer control.
Researchers at Mayo Clinic found that pazopanib significantly decreased progression rate in patients with metastatic, rapidly progressive differentiated thyroid cancers. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.
A retrospective study of 223 patients with terminal cancer found that opioid use was both safe and effective in the home setting. Patients who received higher doses had a longer median survival time compared to those who received lower doses.
The study found significant disparities in survival rates among Asian-Americans diagnosed with liver cancer, with Laotian/Hmong-Americans having the lowest median survival rate of just one month. The group was also least likely to receive treatment, such as liver transplantation, due to late-stage diagnoses.
Researchers at Dana-Farber Cancer Institute found that multivitamin use did not impact colon cancer outcomes in patients with stage III colon cancer. Multivitamin use had no beneficial effect on patients' survival rates but may have a small association with survival benefits for younger patients and those who are obese.
A study published in JAMA found that gemcitabine was not superior to fluorouracil plus folinic acid in terms of overall survival for patients with resected pancreatic cancer. The study included 1,088 patients and showed no significant difference in survival estimates between the treatment groups.
A study published in Journal of Thoracic Oncology found that using the histoculture drug response assay to guide chemotherapy improves lung cancer survival and prognosis for patients who have undergone surgery. The use of adjuvant chemotherapy based on assay results showed a higher five-year survival rate compared to traditional treatm...
A decade-long trial confirms that early corticosteroids withdrawal improves graft survival rates, patient survival rates, and reduces cardiovascular events in transplant patients. The study shows a significant reduction in non-PTLD cancer risk among ECSWD patients.
A new study found that socioeconomic status predicts survival of Canadian cancer patients, with those from poorer backgrounds facing higher mortality rates. The study also suggests that factors such as cancer biology and access to treatment may play a role in these disparities.
Researchers found that CD74 is expressed on colon epithelial cells, increasing their survival upon MIF stimulation. Stimulation of CD74 led to Akt phophorylation and Bcl-2 expression, resulting in elevated cell survival. This discovery may open a new target for colorectal cancer research.
A study found that high-dose radiation targeting the neural stem cell niche in brain cancer patients doubles their progression-free survival time. Patients who received higher doses experienced 15 months of progression-free survival, while those with lower or no doses had 7.2 months.
A randomized controlled trial found that nitric oxide treatment did not improve overall survival or reduce poor lung development in preterm infants. However, black babies showed a higher survival rate compared to non-black babies. The study suggests that ethnic origin may affect the response to nitric oxide treatment.
Researchers developed two new risk models to predict the survival of HIV patients in sub-Saharan Africa. The models identified key factors such as CD4 cell count, clinical stage, and bodyweight that increase the risk of death. These predictions will aid in clinical decision making and improve treatment outcomes.
A study analyzed the probability of surviving nine types of cancer in Spain, comparing rates to European averages. The results show varying survival rates for different cancers, with some types having high recovery rates (e.g., testicular and skin melanoma) while others have lower rates (e.g., lung cancer).
A study found significant variability in 5-year patient survival rates for lung transplantation centers in the US, with risks of death ranging from 30% lower to 70% higher. Despite controlling for procedural volume, center performance remained significant, suggesting true differences in quality of care.
Researchers analyzed surgical outcomes of non-small cell lung cancer patients over 30 years, finding improved survival rates with earlier stage diagnoses. The increase in patients diagnosed with early-stage adenocarcinoma is thought to contribute significantly to the favorable results.
A new study reveals that disparities in cancer stage and treatment account for the majority of excess deaths among uninsured and Medicaid-insured rectal cancer patients. Improving insurance coverage and reducing cost-related barriers to primary care and high-quality treatment can help mitigate these disparities.
Researchers found that acute neurological toxicity is associated with chronic toxicity and shorter overall survival in high-grade glioma patients. Patients experiencing acute toxicity had a median survival of 7.8 months, compared to 11.8 months for those without.
A study on child survival in rural Bangladesh found that mother's death massively reduces child's chances of survival to age 10 years. The father's death has a negligible effect on child mortality rates, with the greatest impact seen in children aged 2-12 months whose mothers had died.
Patients with stage II colon cancer treated after 1995 had longer time to recurrence, but improved overall survival. Stage III colon cancer patients treated after 1995 also showed improved overall survival without change in time to recurrence compared to those treated before 1995.
Men who choose radiotherapy over surgery for prostate cancer have a 17% improvement in overall survival rate, with patients refusing treatment having a 51% 10-year survival rate. This study highlights the importance of considering treatment options when diagnosed with prostate cancer.
A phase III clinical trial found no significant difference in overall survival between AE-941 and placebo arms for patients with non-small cell lung cancer. The study suggests that shark cartilage-derived products do not support the treatment of lung cancer.
Erlotinib maintenance therapy significantly improves progression-free and overall survival in patients with non-small-cell lung cancer. The treatment is generally well-tolerated, with mild to moderate side effects.
A field study found that intermediate testosterone production is associated with increased survival and reproductive success in male dark-eyed juncos. The researchers also discovered that high and low testosterone levels lead to decreased survival rates, contradicting previous expectations.
Patients who undergo gastric cancer surgery followed by chemotherapy have a lower risk of death and improved disease-free survival compared to those who receive surgery alone. The analysis found an 18% reduction in the risk of death and improved overall survival with chemotherapy.
Researchers found that pre-treatment quality-of-life scores can predict malignancy in patients with pancreatic lesions and survival in those who have cancer. Patients with lower quality-of-life scores were more likely to have poor survival rates.
A systematic review of 111 studies involving 4,394 patients found that a third could undergo resection after neoadjuvant therapy, with similar survival rates to those judged resectable before treatment. The study suggests including locally advanced/unresectable tumors in neoadjuvant protocols.
Researchers investigated COX-2 expression as a prognostic factor in pancreatic cancer, finding no significant correlation between high COX-2 levels and survival rates. High histological grade and nodal involvement remained key predictors of shorter survival.
A new study from Fox Chase Cancer Center suggests that levels of ERCC1 offer a predictive marker of survival in squamous carcinoma of the head and neck. Low ERCC1 levels were associated with increased survival from adjuvant therapy, providing support for personalized medicine in these cancers.
Two studies presented at the International Liver Congress 2010 found that extracorporeal liver support therapy may not improve overall survival, but shows positive effects on dialysis and severe hepatic encephalopathy in patients with cirrhosis. A significant survival benefit was observed in patient subgroups with hepatorenal syndrome ...